Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Allergy | Nursing | Pharmacy | Pulmonology | Journal

Back to Journal Articles

No Superior Method of Adjusting Inhaled Steroids in Asthma

Last Updated: September 11, 2012.

 

Time to treatment failure similar for physician-, biomarker-, symptom-based strategies

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For adults with mild-to-moderate asthma controlled with inhaled corticosteroids, adjustment of corticosteroids based on biomarkers (exhaled nitric oxide) or symptoms does not improve the time to treatment failure compared with physician assessment-based adjustment, according to a study published in the Sept. 12 issue of the Journal of the American Medical Association.

TUESDAY, Sept. 11 (HealthDay News) -- For adults with mild-to-moderate asthma controlled with inhaled corticosteroids, adjustment of corticosteroids based on biomarkers (exhaled nitric oxide) or symptoms does not improve the time to treatment failure compared with physician assessment-based adjustment, according to a study published in the Sept. 12 issue of the Journal of the American Medical Association.

William J. Calhoun, M.D., from the University of Texas Medical Branch in Galveston, and colleagues compared approaches for adjustment of inhaled corticosteroid therapy. A cohort of 342 adults with mild-to-moderate asthma controlled with low-dose corticosteroids were randomly assigned to physician assessment-based adjustment (114 assigned; 101 completed); biomarker-based adjustment (115 assigned; 92 completed); or symptom-based adjustment (113 assigned; 97 completed) for nine months.

The researchers observed no significant difference in the time to treatment failure between the groups. The nine-month Kaplan-Meier failure rates were 22, 20, and 15 percent for physician assessment-based adjustment, biomarker-based adjustment, and symptom-based adjustment, respectively. The hazard ratios for time to first treatment failure with physician assessment-based adjustment versus biomarker-based adjustment and symptom-based adjustment were 1.2 (95 percent confidence interval [CI], 0.6 to 2.3) and 1.6 (95 percent CI, 0.8 to 3.3), respectively.

"Among adults with mild-to-moderate persistent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-based or symptom-based adjustment of inhaled corticosteroids was not superior to physician assessment-based adjustment of inhaled corticosteroids in time to treatment failure," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: SPECT/CT Associated With Improved Survival in Melanoma Next: Review: Omega-3s Do Not Reduce Risk of Cardio Events

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.